Buscar Company filed its unaudited annual report for fiscal year 2026 and expanded its PCAOB audit scope to include fiscal years 2025 and 2026. The company plans to register its common stock with the SEC but has not yet filed the registration statement. Buscar operates four early-stage subsidiaries in gold exploration, sustainable materials, wellness, and digital gaming, all requiring additional capital to reach milestones. Key updates include ongoing permitting for a gold exploration project, development of a hemp-based bioplastic, preparations for wellness product launch, and a gold-rush-themed game targeting a 2027 public launch.
The Buscar Company CEO letter to shareholders provides context for readers interested in basic materials. For readers following this sector, here is Pluang's market snapshot as of Oct 23, 2026 17:11 WIB: Among 83 priced Basic Materials-sector US stocks, 28 rose and 51 fell. Equinox Gold Corp. (EQX) traded at USD 10.25 with a 1-day change of -1.06% and a typical hold time of 8 days, while Fortuna Mining Corp. (FSM) was slightly lower at USD 9.42 with a similar 1-day change of -1.05% and a longer hold time of 14 days. Endeavour Silver Corp. (EXK) stood at USD 7.57, also down by -1.05%, with a strong sell bias of 94% on Pluang and the longest typical hold time of 26 days.
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
